Drug Combination Shows Promising Anti-Tumor Effects on Blood Cancer Cells

Drug combination shows promising anti-tumor effects on blood cancer cells

Researchers at Uppsala University have identified a promising therapeutic approach for the challenging blood cancer multiple myeloma. In a new preclinical study, they demonstrate that a dual treatment with drugs that inhibit epigenetic regulation reduces tumor growth and induces cancer cell death. The findings are published in the journal Blood Advances.

EHA 2025: Early Data Support Tocilizumab Use to Enable Outpatient Talquetamab Dosing in R/R Multiple Myeloma

Sundar Jagannath, MD, discusses how prophylactic tocilizumab reduced cytokine release syndrome incidence and severity with talquetamab in relapsed or refractory (R/R) multiple myeloma.

Extended Follow-Up From MonumenTAL-1 and APP Clinical Insights on Talquetamab Efficacy Outcomes

Panelists discuss updated MonumenTAL-1 trial data demonstrating high response rates and prolonged survival with GPRC5D-targeted bispecific therapy in relapsed/refractory multiple myeloma, emphasizing the favorable efficacy, durability, and tolerability of biweekly dosing, which supports improved patient quality of life and positions the therapy as a key option in managing advanced disease.